REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In ...
Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.
The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...
The Department of Pharmacy, Medical Supplies, Equipment, and Supplies, Ministry of Health of Hamad government has warned all ...
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA ® (pembrolizumab) and KEYTRUDA QLEX™ ...
The case stems from ICIJ’s Cancer Calculus investigation into the world's best-selling drug’s sky-high price and its global ...
FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...
The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. Credit: Antonio Marca / Shutterstock.com. The European Commission (EC) has approved ...
Monotherapy in immunotherapy-ineligible patients improved median PFS to 9.7 vs 6.9 months versus physician’s-choice chemotherapy, with 50% vs 47% objective response rates. Combination therapy in PD-L1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results